Form 4: Cardinal Equity Fund Reports GRDN Stock Sales & Conversions

Cardinal Equity Fund, a member of a 10% owner group, reported sales of Guardian Pharmacy Services Class A common stock and an automatic conversion of Class B to Class A shares.

Summary

• Cardinal Equity Fund, L.P., a member of a 10% owner group of Guardian Pharmacy Services, Inc. (GRDN), reported changes in its beneficial ownership.
• The reporting person sold a total of 321,263 shares of Class A common stock at a price of $20.16 per share over two days.
• Specifically, 270,958 shares were sold on May 27, 2025, and an additional 50,305 shares were sold on May 28, 2025.
• These sales were executed pursuant to an Underwriting Agreement dated May 22, 2025, and were made under a Rule 10b5-1(c) pre-arranged plan.
• On September 27, 2025, 471,057 shares of Class B common stock automatically converted into an equal number of Class A common stock shares on a one-for-one basis.
• Following these transactions, Cardinal Equity Fund beneficially owns 620,851 shares of Class A common stock and 942,114 shares of Class B common stock.
• Further automatic conversions of Class B common stock into Class A common stock are scheduled for March 28, 2026, and September 27, 2026, in substantially equal tranches.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider sales can be perceived negatively, the pre-arranged nature via a 10b5-1 plan mitigates concerns of adverse new information. The stock conversion is a mechanical event, neither inherently positive nor negative for the company's operational performance.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged liquidity event rather than a reaction to new negative information.
• The automatic conversion of Class B to Class A common stock increases the float and liquidity of Class A shares.

Negatives

• A significant sale of 321,263 shares of Class A common stock by a 10% owner could be perceived as a negative signal by the market, despite being pre-arranged.

Risks

• The market perception of insider sales, even if pre-planned, could lead to short-term downward pressure on the stock price.
• Future tranches of Class B to Class A conversions will continue to increase the Class A share count, potentially diluting existing Class A shareholders if not offset by growth.

Future Outlook

The filing indicates future automatic conversions of Class B common stock into Class A common stock are scheduled for March 28, 2026, and September 27, 2026, in substantially equal tranches, which will further increase the Class A share count.

Industry Context

This filing reflects an insider transaction by a significant owner, which is a routine disclosure for publicly traded companies. The conversion of Class B to Class A shares is a common mechanism for dual-class stock structures to simplify capital structure over time or increase public float.

Stakeholder Impact

• Shareholders may observe a temporary increase in trading volume and potential price volatility due to the significant share sales by a 10% owner.
• The conversion of Class B to Class A shares will increase the public float of Class A common stock, potentially improving liquidity for Class A shareholders.

Next Steps

• Further automatic conversions of Class B common stock into Class A common stock are scheduled for March 28, 2026.
• The final tranche of automatic conversions of Class B common stock into Class A common stock is scheduled for September 27, 2026.

Key Dates

Recommendation

The filing details pre-arranged insider sales and an automatic stock conversion, which are mechanical events rather than indicators of fundamental changes in the company's performance or outlook. While insider sales can sometimes signal concerns, the 10b5-1 plan suggests a planned liquidity event. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient new information to warrant a change in investment thesis, but investors should monitor future filings and company performance.

Keywords

Guardian Pharmacy Services, GRDN, Cardinal Equity Fund, SEC Form 4, Insider Trading, Stock Sales, Class A Common Stock, Class B Common Stock, Stock Conversion, 10b5-1 Plan